Key Highlights

● Illumina reported third-quarter Revenue of $1.13 billion against $1.15 billion expected.

● Adjusted Earnings of $1.44 a share beat the $1.36 consensus.

● The company guided 2026 revenue to $4.64 billion to $4.66 billion.

● The slide contrasted with health care leading the S&P 500 in regular trading.

Illumina (NASDAQ:ILMN) topped profit forecasts on Thursday evening, but a revenue shortfall was enough to send the gene-sequencing leader sharply lower in extended trading.

The numbers behind the drop

Illumina, the San Diego company whose machines power much of the world's DNA sequencing, reported third-quarter revenue of $1.13 billion after the closing bell on Thursday, October 29. Analysts had been looking for $1.15 billion. The gap is small in dollar terms, but for a company whose investors are watching closely for signs of a durable recovery, missing on the Top Line carried outsized weight.

The stock tumbled in after-hours trading following the release, placing it among the heaviest decliners in the Russell 1000 during the extended session. The selling came despite a clean beat on the bottom line: adjusted earnings reached $1.44 a share, ahead of the $1.36 consensus.

Guidance in focus

Alongside the quarter, Illumina laid out a full-year 2026 framework calling for revenue of $4.64 billion to $4.66 billion and earnings of $5.40 to $5.45 a share. That narrow range gives investors a clear marker for the fourth quarter, but the extended-trading reaction suggests the market had hoped for more momentum in sales.

For a tools company, revenue is often read as the clearest signal of customer demand. Labs, hospitals and research institutions buy sequencers and, more importantly, the consumables that run on them. When sales fall short even as profit beats, traders tend to conclude that cost control, rather than growth, is doing the heavy lifting, and they price the stock accordingly.

An awkward contrast with health care's big day

The after-hours slide stood in sharp contrast with the regular session, when health care was the best-performing sector in the S&P 500. Eli Lilly (NYSE:LLY) and Merck (NYSE:MRK) both rallied after beating expectations, and the drug-focused IHE exchange-traded fund climbed as investors rotated toward defensive and earnings-backed names. Illumina's report landed after that rally had already run its course.

The broader tape was split. The S&P 500 slipped 23.59 points to 7,720.39, ending a three-day winning streak, while the Nasdaq Composite fell 365.13 points to 26,184.72 as Alphabet (NASDAQ:GOOGL) suffered its worst day since its 2004 IPO. Small caps, meanwhile, rallied, with the Russell 2000 gaining 28.71 points to 2,859.22.

A crowded evening of reports

Illumina was one of several companies that reported after the bell and met a cold reception. Stryker (NYSE:SYK), the medical device maker, fell sharply in extended trading after its revenue and full-year profit outlook came in light, while Amazon (NASDAQ:AMZN) and Intel (NASDAQ:INTC) dragged on Nasdaq-100 futures. DexCom (NASDAQ:DXCM) and Gilead Sciences (NASDAQ:GILD) moved the other way after hours on stronger results, a reminder that the health care group was hardly uniform.

The mood across markets also reflected the macro backdrop. Third-quarter GDP accelerated from the second quarter and beat forecasts, and September PCE Inflation ran hot. One Wealth advisor said, "Today's data strengthens the case for another rate increase in December." Higher-for-longer rate expectations tend to weigh on growth-oriented names that are expected to deliver earnings further into the future.

What to watch

The key question is whether Friday's regular session confirms or softens the after-hours move. Extended-trading prices are often set on thin Volume and can change once the full market is open.

Beyond the opening print, investors will want detail on what held revenue back and whether the shortfall reflects timing or softer demand. The $4.64 billion to $4.66 billion guidance range will serve as the benchmark for the fourth quarter. On the macro side, Friday's Employment Cost index and the run-up to the Fed's December 8–9 meeting will set the tone for rate-sensitive growth stocks.